Immunohistochemical expression of P53 protein in nephroblastoma: a predictor of unfavorable prognosis.

IF 2.1 Q3 ONCOLOGY
Emmanuel D Morgan, James J Yahaya, Advera I Ngaiza, Emmanuel Othieno, Okwi A Livex
{"title":"Immunohistochemical expression of P53 protein in nephroblastoma: a predictor of unfavorable prognosis.","authors":"Emmanuel D Morgan,&nbsp;James J Yahaya,&nbsp;Advera I Ngaiza,&nbsp;Emmanuel Othieno,&nbsp;Okwi A Livex","doi":"10.1186/s43046-023-00183-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Immunohistochemical expression of P53 protein is so closely related to status of mutation of P53 gene which is tightly linked with pathogenesis of nephroblastoma or Wilms tumor. This study aims to determine the immunohistochemical expression of P53 protein and its predictors in formalin-fixed paraffin-embedded tissue blocks of patients with nephroblastoma.</p><p><strong>Materials and methods: </strong>A series of 83 histologically diagnosed cases of nephroblastoma from formalin-fixed paraffin-embedded tissue blocks archived at the Department of Pathology, Makerere University, in Kampala, Uganda, were analyzed. Monoclonal anti-p53 antibody (DO-7, DAKO) was used to assess the expression of P53 protein expression. Multivariable logistic regression analysis was performed to determine the predictors of P53 protein immunohistochemical expression, and statistical significance was considered when p-value was less than 0.05.</p><p><strong>Results: </strong>Most (42.2%, n = 35) of the cases were in advanced tumor stages (III-V), and almost one-quarter (21.7%, n = 18) of the cases were in high-risk group. The immunohistochemical expression of P53 protein was (8.4%, n = 7), and there were more (83.3%, n = 5) positive anaplastic cases for P53 protein compared with (2.6%, n = 2) of P53 expression for non-anaplastic cases. High risk (AOR = 3.42, 95% CI = 7.91-12.55, p = 0.037) and anaplasia (AOR = 1.41, 95% CI = 13.85-4.46, p = 0.001) were potential predictors of immunohistochemical expression of P53 protein.</p><p><strong>Conclusion: </strong>Most of patients with nephroblastoma in resources-limited settings are diagnosed with advanced clinical stages. Association of P53 protein with anaplasia found in this study indicates the possibility of having novel target therapy for treatment of patients with anaplastic form of nephroblastoma with a focus of identifying molecules that lead to its suppression in such subpopulations of patients with nephroblastoma.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"35 1","pages":"23"},"PeriodicalIF":2.1000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-023-00183-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Immunohistochemical expression of P53 protein is so closely related to status of mutation of P53 gene which is tightly linked with pathogenesis of nephroblastoma or Wilms tumor. This study aims to determine the immunohistochemical expression of P53 protein and its predictors in formalin-fixed paraffin-embedded tissue blocks of patients with nephroblastoma.

Materials and methods: A series of 83 histologically diagnosed cases of nephroblastoma from formalin-fixed paraffin-embedded tissue blocks archived at the Department of Pathology, Makerere University, in Kampala, Uganda, were analyzed. Monoclonal anti-p53 antibody (DO-7, DAKO) was used to assess the expression of P53 protein expression. Multivariable logistic regression analysis was performed to determine the predictors of P53 protein immunohistochemical expression, and statistical significance was considered when p-value was less than 0.05.

Results: Most (42.2%, n = 35) of the cases were in advanced tumor stages (III-V), and almost one-quarter (21.7%, n = 18) of the cases were in high-risk group. The immunohistochemical expression of P53 protein was (8.4%, n = 7), and there were more (83.3%, n = 5) positive anaplastic cases for P53 protein compared with (2.6%, n = 2) of P53 expression for non-anaplastic cases. High risk (AOR = 3.42, 95% CI = 7.91-12.55, p = 0.037) and anaplasia (AOR = 1.41, 95% CI = 13.85-4.46, p = 0.001) were potential predictors of immunohistochemical expression of P53 protein.

Conclusion: Most of patients with nephroblastoma in resources-limited settings are diagnosed with advanced clinical stages. Association of P53 protein with anaplasia found in this study indicates the possibility of having novel target therapy for treatment of patients with anaplastic form of nephroblastoma with a focus of identifying molecules that lead to its suppression in such subpopulations of patients with nephroblastoma.

肾母细胞瘤中P53蛋白的免疫组织化学表达:不良预后的预测因子。
目的:P53蛋白的免疫组化表达与P53基因的突变状态密切相关,而P53基因的突变与肾母细胞瘤或肾母细胞瘤的发病密切相关。本研究旨在检测肾母细胞瘤患者福尔马林固定石蜡包埋组织块中P53蛋白的免疫组织化学表达及其预测因子。材料和方法:对乌干达坎帕拉Makerere大学病理学系记录的83例经福尔马林固定石蜡包埋组织块组织学诊断的肾母细胞瘤病例进行分析。采用单克隆抗P53抗体(DO-7, DAKO)检测P53蛋白表达情况。采用多变量logistic回归分析确定P53蛋白免疫组化表达的预测因子,p值小于0.05认为有统计学意义。结果:绝大多数(42.2%,n = 35)为晚期肿瘤(III-V期),近1 / 4 (21.7%,n = 18)为高危组。P53蛋白免疫组化表达为(8.4%,n = 7), P53蛋白间变性阳性病例(83.3%,n = 5)多于非间变性病例(2.6%,n = 2)。高风险(AOR = 3.42, 95% CI = 7.91 ~ 12.55, p = 0.037)和发育不全(AOR = 1.41, 95% CI = 13.85 ~ 4.46, p = 0.001)是P53蛋白免疫组化表达的潜在预测因子。结论:在资源有限的情况下,大多数肾母细胞瘤患者被诊断为晚期临床阶段。本研究中发现的P53蛋白与间变性之间的关联表明,有可能为间变性肾母细胞瘤患者提供新的靶向治疗方法,重点是识别导致其在肾母细胞瘤患者亚群中被抑制的分子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信